Polynuclear ruthenium, osmium and gold complexes. the quest for innovative anticancer chemotherapeutics

Current Topics in Medicinal Chemistry

Volumn 11, Issue 21, 2011, Pages 2688-2702

  Hartinger, Christian G ^a   Phillips, Andrew D ^b   Nazarov, Alexey A ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c EPFL   (Switzerland)

Author keywords

Bioorganometallics; Cancer chemotherapy; Coordination compounds; Metalloclusters; Mode of action; Polynuclear complexes

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; GOLD COMPLEX; NUCLEIC ACID BASE; OSMIUM; RUTHENIUM;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; NONHUMAN; PHOTOACTIVATION; REVIEW;

ANTINEOPLASTIC AGENTS; COORDINATION COMPLEXES; CROSS-LINKING REAGENTS; DNA; ENZYME INHIBITORS; GOLD; HUMANS; MODELS, MOLECULAR; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OSMIUM; PHOTOCHEMICAL PROCESSES; RUTHENIUM;

EID: 80055073350     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798040769     Document Type: Review

References (143)

1. Galanski, M.; Jakupec, M. A.; Keppler, B. K. Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Curr. Med. Chem., 2005, 12, 2075-2094.
2. Heffeter, P.; Jungwirth, U.; Jakupec, M.; Hartinger, C.; Galanski, M.; Elbling, L.; Micksche, M.; Keppler, B.; Berger, W. Resistance against novel anticancer metal compounds: Differences and similarities. Drug Res. Upd., 2008, 11, 1-16.
3. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumor metal compounds: more than theme and variations. Dalton Trans., 2008, 183-194.
4. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106, 2224-2248.
5. Sun, X.; Tsang, C.-N.; Sun, H. Identification and characterization of metallodrug binding proteins by (metallo)proteomics. Metallomics, 2009, 1, 25-31.
6. Zhang, C. X.; Lippard, S. J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol., 2003, 7, 481-489.
7. van Zutphen, S.; Reedijk, J. Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. Coord. Chem. Rev., 2005, 249, 2845-2853.
8. Haag, R.; Kratz, F. Polymer therapeutics: concepts and applications. Angew. Chem., Int. Ed., 2006, 45, 1198-1215.
9. Hartinger, C. G.; Nazarov, A. A.; Ashraf, S. M.; Dyson, P. J.; Keppler, B. K. Carbohydrate-metal complexes and their potential as anticancer agents. Curr. Med. Chem., 2008, 15, 2574-2591.
10. Farrell, N. P.; De Almeida, S. G.; Skov, K. A. Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies. J. Am. Chem. Soc., 1988, 110, 5018-5019.
11. Farrell, N. In: Metal Ions in Biological Systems; Sigel, A.; Sigel, H., Eds. 2004; Vol. 42, p 251-296.
12. Qu, Y.; Gama de Almeida, S.; Farrell, N. Synthetic strategies for dinuclear platinum complexes containing inequivalent coordination spheres. Design of complexes capable of specific attach at one platinum center. Inorg. Chim. Acta, 1992, 201, 123-129.
13. Harris, A. L.; Yang, X.; Hegmans, A.; Povirk, L.; Ryan, J. J.; Kelland, L.; Farrell, N. P. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. enhancement of cellular uptake with charge. Inorg. Chem., 2005, 44, 9598-9600.
14. Zhao, G.; Lin, H.; Zhu, S.; Sun, H.; Chen, Y. Synthesis and biological activity of binuclear platinum complexes containing two monofunctional cis-[Pt(NH3)2Cl]+ units bridged by 4,4'-dipyridyl selenides or sulfides. Anti-Cancer Drug Des., 1998, 13, 769-777.
15. Kasparkova, J.; Novakova, O.; Vrana, O.; Farrell, N.; Brabec, V. Effect of geometric isomerism in dinuclear platinum antitumor complexes on dna interstrand cross-linking. Biochemistry, 1999, 38, 10997-11005.
16. Manzotti, C.; Pratesi, G.; Menta, E.; Domenico, R. D.; Cavalletti, E.; Fiebig, H. H.; Kelland, L. R.; Farrell, N.; Polizzi, D.; Supino, R.; Pezzoni, G.; Zunino, F. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin. Cancer Res., 2000, 6, 2626-2634.
17. Jodrell, D. I.; Evans, T. R. J.; Steward, W.; Cameron, D.; Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.; Dobbs, N.; Camboni, G.; Gatti, B.; De Braud, F. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer, p 2004, 40, 1872-1877.
18. Kostova, I. Platinum complexes as anticancer agents. Recent Patents on Anti-Cancer Drug Discov. 2006, 1, 1-22.
19. Hensing, T. A.; Hanna, N. H.; Gillenwater, H. H.; Camboni, M. G.; Allievi, C.; Socinski, M. A. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anti-Cancer Drugs, 2006, 17, 697-704.
20. Huq, F.; Daghriri, H.; Yu, J. Q.; Tayyem, H.; Beale, P.; Zhang, M. Synthesis, characterisation, activities, cell uptake and DNA binding of [{trans-PtCl(NH3)2}{μ-(H2N(CH2)6NH2)}{trans-PdCl(NH3)2}](NO3)Cl. Eur. J. Med. Chem., 2004, 39, 947-958.
21. van der Schilden, K.; Garcia, F.; Kooijman, H.; Spek, A. L.; Haasnoot, J. G.; Reedijk, J. A highly flexible dinuclear ruthenium(II)-platinum(II) complex: crystal structure and binding to 9-ethylguanine. Angew. Chem., Int. Ed., 2004, 43, 5668-5670.
22. de Hoog, P.; Boldron, C.; Gamez, P.; Sliedregt-Bol, K.; Roland, I.; Pitie, M.; Kiss, R.; Meunier, B.; Reedijk, J. New approach for the preparation of efficient DNA cleaving agents: ditopic copper platinum complexes based on 3-clip-phen and cisplatin. J. Med. Chem., 2007, 50, 3148-3152.
23. Dyson, P. J.; Sava, G. Metal-based antitumor drugs in the post genomic era. Dalton Trans., 2006, 1929-1933.
24. Hartinger, C. G.; Dyson, P. J. Bioorganometallic chemistry from teaching paradigms to medicinal application. Chem. Soc. Rev., 2009, 38, 391-401.
25. Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019/FFC14A a new redox-active anticancer agent preclinical development and results of a clinical phase i study in tumor patients. Chem. Biodivers., 2008, 5, 2140-2155.
26. Rademaker-Lakhai, J. M.; van den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res., 2004, 10, 3717-3727.
27. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From bench to bedside preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
28. Berger, M. R.; Garzon, F. T.; Keppler, B. K.; Schmaehl, D. Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res., 1989, 9, 761-765.
29. Dittrich, C.; Scheulen, M. E.; Jaehde, U.; Kynast, B.; Gneist, M.; Richly, H.; Schaad, S.; Arion, V. B.; Keppler, B. K. Phase I and pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)ruthenate(III)]/indazolehydrochloride (1:1.1) (FFC14A, KP1019) in patients with solid tumors a study of the CESAR central european society for anticancer drug research EWIV Proc. Am. Assoc. Cancer Res., 2005, 46, P472.
30. Sava, G.; Pacor, S.; Mestroni, G.; Alessio, E. Clin. Exp. Metastasis, 1992, 10, 273.
31. Sava, G.; Alessio, E.; Bergamo, A.; Mestroni, G. Sulfoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumor metastases. Top. Biol. Inorg. Chem.,1999, 1, 143-169.
32. Keppler, B. K.; Lipponer, K. G.; Stenzel, B.; Kratz, F. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K., Ed.; VCH: Weinheim, 1993, p 187-220.
33. Pieper, T.; Borsky, K.; Keppler, B. K. Non-platinum antitumor compounds. Top. Biol. Inorg. Chem., 1999, 1, 171-199.
34. Clarke, M. J.; Zhu, F.; Frasca, D. R. Non-Platinum Chemotherapeutic Metallopharmaceuticals. Chem. Rev., 1999, 99, 2511-2533.
35. Clarke, M. J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2003, 236, 209-233.
36. Kratz, F.; Hartmann, M.; Keppler, B.; Messori, L. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J. Biol. Chem.,1994, 269, 2581-2588.
37. Smith, C. A.; Sutherland-Smith, A. J.; Keppler, B. K.; Kratz, F.; Baker, E. N. Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses. J. Biol. Inorg. Chem., 1996, 1, 424-431.
38. Sulyok, M.; Hann, S.; Hartinger, C. G.; Keppler, B. K.; Stingeder, G.; Koellensperger, G. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J. Anal. At. Spectrom., 2005, 20, 856-863.
39. Klausner, R. D.; Van Renswoude, J.; Ashwell, G.; Kempf, C.; Schechter, A. N.; Dean, A.; Bridges, K. R. Receptor-mediated endocytosis of transferrin in K562 cells. J. Biol. Chem., 1983, 258, 4715-4724.
40. Kelman, A. D.; Clarke, M. J.; Edmonds, S. D.; Peresie, H. J. Biological activity of ruthenium purine complexes. J. Clin. Hematol. Oncol., 1977, 7, 274-288.
41. Anghileri, L. J. Radioactive ruthenium red accumulation by tumors. Potential scanning agent. Strahlentherapie, 1975, 149, 173-175.
42. Oberc-Greenwood, M. A.; Muul, L. M.; Gately, M. K.; Kornblith, P. L.; Smith, B. H. Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro. J. Neurooncol., 1986, 3, 387-396.
43. Anghileri, L. J.; Marchal, C.; Matrat, M.; Crone-Escanye, M. C.; Robert, J. Hyperthermia inhibition of tumor cells growth in the presence of ruthenium red. Neoplasma, 1986, 33, 603-608.
44. Hurley, T. W. Kinetics of high-affinity calcium sequestration in permeabilized rat pancreatic acini. Am. J. Physiol., 1988, 254, C621-C627.
45. Emerson, J.; Clarke, M. J.; Ying, W. L.; Sanadi, D. R. The component of ruthenium red responsible for inhibition of mitochondrial calcium ion transport. Spectra, electrochemistry, and aquation kinetics. Crystal structure of μ-O [(HCO2)(NH3)4Ru]2Cl3. J. Am. Chem. Soc., 1993, 115, 11799-11805.
46. Ying, W. L.; Emerson, J.; Clarke, M. J.; Sanadi, D. R. Inhibition of mitochondrial calcium ion transport by an oxo-bridged dinuclear ruthenium ammine complex. Biochemistry, 1991, 30, 4949-4952.
47. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Growth inhibition of Lewis lung carcinoma by an inorganic dye, Ruthenium Red. Gann, 1980, 71, 151-154.
48. Bergamo, A.; Stocco, G.; Gava, B.; Cocchietto, M.; Alessio, E.; Serli, B.; Iengo, E.; Sava, G. Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J. Pharmacol. Exp. Ther., 2003, 305, 725-732.
49. Alessio, E.; Iengo, E.; Zorzet, S.; Bergamo, A.; Coluccia, M.; Boccarelli, A.; Sava, G. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2 [{trans-RuCl4(Me2SO)}2(μ-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation. J. Inorg. Biochem., 2000, 79, 173-177.
50. Hotze, A. C. G.; Kariuki, B. M.; Hannon, M. J. Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs. Angew. Chem., Int. Ed., 2006, 45, 4839-4842.
51. Pascu, G. I.; Hotze, A. C. G.; Sanchez-Cano, C.; Kariuki, B. M.; Hannon, M. J. Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines. Angew. Chem., Int. Ed., 2007, 46, 4374-4378.
52. Malina, J.; Hannon, M. J.; Brabec, V. Interaction of dinuclear ruthenium(II) supramolecular cylinders with DNA: sequence-specific binding, unwinding, and photocleavage. Chem. Eur. J., 2008, 14, 10408-10414.
53. McDonnell, U.; Kerchoffs, J. M. C. A.; Castineiras, R. P. M.; Hicks, M. R.; Hotze, A. C. G.; Hannon, M. J.; Rodger, A. Synthesis and cytotoxicity of dinuclear complexes containing ruthenium(II) bipyridyl units linked by a bis(pyridylimine) ligand. Dalton Trans., 2008, 667-675.
54. McDonnell, U.; Hicks, M. R.; Hannon, M. J.; Rodger, A. DNA binding and bending by dinuclear complexes comprising ruthenium polypyridyl centres linked by a bis(pyridylimine) ligand. J. Inorg. Biochem., 2008, 102, 2052-2059.
55. Corral, E.; Hotze, A. C. G.; den Dulk, H.; Leczkowska, A.; Rodger, A.; Hannon, M. J.; Reedijk, J. Ruthenium polypyridyl complexes and their modes of interaction with DNA: Is there a correlation between these interactions and the antitumor activity of the compounds? J. Biol. Inorg. Chem., 2009, 14, 439-448.
56. Mishra, L.; Sinha, R. Tris(benzimidazol-2-ylmethyl)amine as a versatile building block in Ru(II) polypyridyl chemistry. Monatsh. Chem., 2002, 133, 59-69.
57. Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun., 2005, 4764-4776.
58. Ang, W. H.; Dyson, P. J. Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem.,2006, 4003-4018.
59. Allardyce, C. S.; Dyson, P. J. Medicinal properties of organometallic compounds. Topics Organometallic Chem., 2006, 17, 177-210.
60. Süss-Fink, G. Arene ruthenium complexes as anticancer agents. Dalton Trans., 2010, 39, 1673-1688.
61. Mendoza-Ferri, M. G.; Hartinger, C. G.; Eichinger, R. E.; Stolyarova, N.; Jakupec, M. A.; Nazarov, A. A.; Severin, K.; Keppler, B. K. Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds. Organometallics 2008, 27, 2405-2407.
62. Mendoza-Ferri, M. G.; Hartinger, C. G.; Mendoza, M. A.; Groessl, M.; Egger, A. E.; Eichinger, R. E.; Mangrum, J. B.; Farrell, N. P.; Maruszak, M.; Bednarski, P. J.; Klein, F.; Jakupec, M. A.; Nazarov, A. A.; Severin, K.; Keppler, B. K. Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J. Med. Chem., 2009, 52, 916-925.
63. Mendoza-Ferri, M. G.; Hartinger, C. G.; Nazarov, A. A.; Kandioller, W.; Severin, K.; Keppler, B. K. Modifying the structure of dinuclear ruthenium complexes with antitumor activity. Appl. Organomet. Chem., 2008, 22, 326-332.
64. II arene antitumor complexes in cell-free media. Biochem. Pharmacol., 2009, 77, 364-374.
65. Mendoza-Ferri, M. G.; Hartinger, C. G.; Nazarov, A. A.; Eichinger, R. E.; Jakupec, M. A.; Severin, K.; Keppler, B. K. Influence of the arene ligand, the number and type of metal centers, and the leaving group on the in vitro antitumor activity of polynuclear organometallic compounds. Organometallics, 2009, 28, 6260-6265.
66. Morris, R. E.; Sadler, P. J.; Chen, H.; Jodrell, D.; The University Court, The University of Edinburgh, UK: WO, 2001, p 36.
67. Morris, R. E.; Sadler, P. J.; Jodrell, D.; Chen, H.; University Court, The University of Edinburgh, UK: WO, 2002, p 32.
68. Chen, H.; Parkinson, J. A.; Novakova, O.; Bella, J.; Wang, F.; Dawson, A.; Gould, R.; Parsons, S.; Brabec, V.; Sadler, P. J. Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers. Proc. Natl. Acad. Sci. USA, 2003, 100, 14623-14628.
69. Schmitt, F.; Govindaswamy, P.; Suess-Fink, G.; Ang, W. H.; Dyson, P. J.; Juillerat-Jeanneret, L.; Therrien, B. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J. Med. Chem., 2008, 51, 1811-1816.
70. Baban, D. F.; Seymour, L. W. Control of tumor vascular permeability. Adv. Drug Deliv. Rev., 1998, 34, 109-119.
71. Govender, P.; Antonels, N. C.; Mattsson, J.; Renfrew, A. K.; Dyson, P. J.; Moss, J. R.; Therrien, B.; Smith, G. S. Anticancer activity of multinuclear arene ruthenium complexes coordinated to dendritic polypyridyl scaffolds. J. Organomet. Chem., 2009, 694, 3470-3476.
72. 6+: a trojan horse for cancer cells. Angew. Chem., Int. Ed., 2008, 47, 3773-3776.
73. Zava, O.; Mattsson, J.; Therrien, B.; Dyson, P. J. Evidence for Drug Release from a Metalla-Cage Delivery Vector Following Cellular Internalisation. Chem. Eur. J., 2010, 16, 1428-1431.
74. Holzer, A. K.; Katano, K.; Klomp, L. W. J.; Howell, S. B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 2004, 10, 6744-6749.
75. Kalayda Ganna, V.; Wagner, C. H.; Buss, I.; Reedijk, J.; Jaehde, U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer, 2008, 8, 175
76. Hall, M. D.; Okabe, M.; Shen, D.-W.; Liang, X.-J.; Gottesman, M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 495-535.
77. Dobson, P. D.; Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discov., 2008, 7, 205-220.
78. Mattsson, J.; Govindaswamy, P.; Renfrew, A. K.; Dyson, P. J.; Stepnicka, P.; Suss-Fink, G.; Therrien, B. Synthesis, molecular structure, and anticancer activity of cationic arene ruthenium metallarectangles. Organometallics, 2009, 28, 4350-4357.
79. Barry, N. P. E.; Edafe, F.; Dyson, P. J.; Therrien, B. Anticancer activity of osmium metalla-rectangles. Dalton Trans., 2010, 39, 2816-2820.
80. Linares, F.; Galindo, M. A.; Galli, S.; Angustias Romero, M.; Navarro, J. A. R.; Barea, E. Tetranuclear coordination assemblies based on half-sandwich ruthenium(ii) complexes: noncovalent binding to DNA and cytotoxicity. Inorg. Chem., 2009, 48, 7413-7420.
81. Auzias, M.; Therrien, B.; Suess-Fink, G.; Stepnicka, P.; Ang, W. H.; Dyson, P. J. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity. Inorg. Chem., 2008, 47, 578-583.
82. Nguyen, A.; Vessieres, A.; Hillard, E. A.; Top, S.; Pigeon, P.; Jaouen, G. Ferrocifens and ferrocifenols as new potential weapons against breast cancer. Chimia, 2007, 61, 716-724.
83. 6-arene)(NC3H3N(CH2)2O2C-C5H4FeC5H5)Cl2]. J. Organomet. Chem., 2009, 694, 855-861.
84. Huxham, L. A.; Cheu, E. L. S.; Patrick, B. O.; James, B. R. The synthesis, structural characterization, and in vitro anti-cancer activity of chloro(p-cymene) complexes of ruthenium(II) containing a disulfoxide ligand. Inorg. Chim. Acta, 2003, 352, 238-246.
85. Phillips, A. D.; Gonsalvi, L.; Romerosa, A.; Vizza, F.; Peruzzini, M. Coordination chemistry of 1,3,5-triaza-7-phosphaadamantane (PTA) Transition metal complexes and related catalytic, medicinal and photoluminescent applications. Coord. Chem. Rev., 2004, 248, 955-993.
86. II-[9]aneS3 analogues. Eur. J. Inorg. Chem., 2005, 3423-3434.
87. II [9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity. J. Inorg. Biochem., 2008, 102, 1120-1133.
88. II-[9]aneS3 complexes with dicarboxylate ligands: Synthesis, characterization and chemical behavior. Dalton Trans., 2007, 4048-4058.
89. Bratsos, I.; Serli, B.; Zangrando, E.; Katsaros, N.; Alessio, E. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity. Inorg. Chem., 2007, 46, 975-992.
90. Alessio, E.; Bergamo, A.; Bratsos, I.; Sava, G.; Serli, B.; Zangrande, E.; Fondazione Carlo e Dirce Callerio Onlus, Italy; Universita' degli Studi di Trieste: IT, 2005, p 43.
91. Chifotides, H. T.; Dunbar, K. R. Interactions of metal-metal-bonded antitumor active complexes with DNA fragments and DNA. Acc. Chem. Res., 2005, 38, 146-156.
92. Aquino, M. A. S. Diruthenium and diosmium tetracarboxylates: synthesis, physical properties and applications. Coord. Chem. Rev., 1998, 170, 141-202.
93. Allardyce, C. S.; Dyson, P. J. The interactions of low oxidation state transition metal clusters with DNA: potential applications in cancer therapy. J. Cluster Sci., 2001, 12, 563-569.
94. Keppler, B. K.; Henn, M.; Juhl, U. M.; Berger, M. R.; Niebel, R.; Wagner, F. E. In Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy; Clarke, M. J., Ed.; Springer-Verlag: Heidelberg, 1989, p 41-70.
95. Therrien, B.; Ang, W. H.; Cherioux, F.; Vieille-Petit, L.; Juillerat-Jeanneret, L.; Suess-Fink, G.; Dyson, P. J. Remarkable anticancer activity of triruthenium-arene clusters compared to tetraruthenium-arene clusters. J. Cluster Sci., 2007, 18, 741-752.
96. Therrien, B.; Suess-Fink, G.; Dyson, P.; Ang, W. H.; Université de Neuchatel, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland;: EP, 2009, p 13.
97. Schmitt, F.; Auzias, M.; Stepnicka, P.; Sei, Y.; Yamaguchi, K.; Suss-Fink, G.; Therrien, B.; Juillerat-Jeanneret, L. Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells. J. Biol. Inorg. Chem., 2009, 14, 693-701.
98. Reddy, V. D.; Dayal, D.; Cosenza, S. C.; Ramana Reddy, M. V.; Pearl, W. C.; Adams, R. D. Glycal-ruthenium carbonyl clusters: Syntheses, characterization, and anticancer activity. J. Organomet. Chem., 2009, 694, 959-967.
99. Kong, K. V.; Leong, W. K.; Ng, S. P.; Nguyen, T. H.; Lim, L. H. K. Osmium carbonyl clusters: a new class of apoptosis inducing agents. ChemMedChem, 2008, 3, 1269-1275.
100. Kong, K. V.; Leong, W. K.; Lim, L. H. K. Osmium carbonyl clusters containing labile ligands hyperstabilize microtubules. Chem. Res. Toxicol., 2009, 22, 1116-1122.
101. Rosenberg, E.; Spada, F.; Sugden, K.; Martin, B.; Milone, L.; Gobetto, R.; Viale, A.; Fiedler, J. Synthesis, characterization and DNA binding affinities of water-soluble benzoheterocycle triosmium clusters. J. Organomet. Chem., 2003, 668, 51-58.
102. Rosenberg, E.; Spada, F.; Sugden, K.; Martin, B.; Gobetto, R.; Milone, L.; Viale, A. Selective covalent binding of a positively charged water-soluble benzoheterocycle triosmium cluster to single and double-stranded DNA. J. Organomet. Chem., 2004, 689, 4729-4738.
103. Nervi, C.; Gobetto, R.; Milone, L.; Viale, A.; Rosenberg, E.; Spada, F.; Rokhsana, D.; Fiedler, J. Solution properties, electrochemical behavior and protein interactions of water soluble triosmium carbonyl clusters. J. Organomet. Chem., 2004, 689, 1796-1805.
104. Colangelo, D.; Ghiglia, A.; Ghezzi, A.; Ravera, M.; Rosenberg, E.; Spada, F.; Osella, D. Water-soluble benzoheterocycle triosmium clusters as potential inhibitors of telomerase enzyme. J. Inorg. Biochem., 2005, 99, 505-512.
105. Nakamura, T. M.; Morin, G. B.; Chapman, K. B.; Weinrich, S. L.; Andrews, W. H.; Lingner, J.; Harley, C. B.; Cech, T. R. Telomerase catalytic subunit homologs from fission yeast and human. Science, 1997, 277, 955-959.
106. Berners-Price, S. J.; Sadler, P. J. In Structure and Bonding; Springer-Verlag Berlin, Heidelberg: Berlin, 1988; Vol. 70, p 27-102.
107. Shaw, C. F., III. Gold-based therapeutic agents. Chem. Rev., 1999, 99, 2589-2600.
108. Barnard, P. J.; Berners-Price, S. J. Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev., 2007, 251, 1889-1902.
109. Gabbiani, C.; Casini, A.; Messori, L. Gold(III) compounds as anticancer drugs. Gold Bull., 2007, 40, 73-88.
110. Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev., 2009, 253, 1670-1681.
111. Bindoli, A.; Rigobello, M. P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 2009, 253, 1692-1707.
112. Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev., 2010, 30(3),550-580
113. Simon, T. M.; Kunishima, D. H.; Vibert, G. J.; Lorber, A. Screening trial with the coordinated gold compound Auranofin using mouse lymphocytic leukemia P388. Cancer Res., 1981, 41, 94-97.
114. Shaw, C. F., III; Beery, A.; Stocco, G. C. Antitumor activity of two binuclear gold(I) complexes with bridging dithiolate ligands. Inorg. Chim. Acta, 1986, 123, 213-216.
115. Barreiro, E.; Casas, J. S.; Couce, M. D.; Sanchez, A.; Sanchez-Gonzalez, A.; Sordo, J.; Varela, J. M.; Vazquez Lopez, E. M. Dinuclear triphenylphosphinegold(I) sulfanylcarboxylates: Synthesis, structure and cytotoxic activity against cancer cell lines. J. Inorg. Biochem., 2010, 104, 551-559.
116. Snyder, R. M.; Mirabelli, C. K.; Johnson, R. K.; Sung, C. M.; Faucette, L. F.; McCabe, F. L.; Zimmerman, J. P.; Whitman, M.; Hempel, J. C.; Crooke, S. T. Modulation of the antitumor and biochemical properties of bis(diphenylphosphine)ethane with metals. Cancer Res., 1986, 46, 5054-5060.
117. Mirabelli, C. K.; Hill, D. T.; Faucette, L. F.; McCabe, F. L.; Girard, G. R.; Bryan, D. B.; Sutton, B. M.; Bartus, J. O.; Crooke, S. T.; Johnson, R. K. Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J. Med. Chem., 1987, 30, 2181-2190.
118. Berners-Price, S. J.; Bowen, R. J.; Fernandes, M. A.; Layh, M.; Lesueur, W. J.; Mahepal, S.; Mtotywa, M. M.; Sue, R. E.; van Rensburg, C. E. J. Gold(I) and silver(I) complexes of 2,3-bis(diphenylphosphino)maleic acid: Structural studies and antitumour activity. Inorg. Chim. Acta, 2005, 358, 4237-4246.
119. Berners-Price, S. J.; Bowen, R. J.; Hambley, T. W.; Healy, P. C. NMR and structural studies of gold(I) chloride adducts with bidentate 2-, 3-and 4-pyridyl phosphines. J. Chem. Soc., Dalton Trans., 1999, 1337-1346.
120. Synder, R. M.; Mirabelli, C. K.; Johnson, R. K.; Sung, C. M.; Faucette, L. F.; McCabe, F. L.; Zimmerman, J. P.; Whitman, M.; Hempel, J. C.; Crooke, S. T. Modulation of the antitumor and biochemical properties of bis(diphenylphosphine)ethane with metals. Cancer Res., 1986, 46, 5054-5060.
121. Berners-Price, S. J.; Mirabelli, C. K.; Johnson, R. K.; Mattern, M. R.; McCabe, F. L.; Faucette, L. F.; Sung, C. M.; Mong, S. M.; Sadler, P. J.; Crooke, S. T. In vivo antitumor activity and in vitro cytotoxic properties of bis [1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res., 1986, 46, 5486-5493.
122. Mirabelli, C. K.; Jensen, B. D.; Mattern, M. R.; Sung, C. M.; Mong, S. M.; Hill, D. T.; Dean, S. W.; Schein, P. S.; Johnson, R. K.; Crooke, S. T. Cellular pharmacology of micro -[1,2-bis(diphenylphosphino)ethane] bis [(1-thio-beta -D-glucopyranosato-S)gold(I)]: a novel antitumor agent. Anti-Cancer Drug Des., 1986, 1, 223-234.
123. McKeage, M. J.; Berners-Price, S. J.; Galettis, P.; Bowen, R. J.; Brouwer, W.; Ding, L.; Zhuang, L.; Baguley, B. C. Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother. Pharmacol., 2000, 46, 343-350.
124. Suresh, D.; Balakrishna, M. S.; Rathinasamy, K.; Panda, D.; Mague, J. T. Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu-I, Au-I) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line. Dalton Trans., 2008, 2285-2292.
125. Kunz, Peter C.; Reiß, Guido J.; Frank, W.; Kläui, W. A novel water-soluble tripodal imidazolyl ligand as a model for the tris(histidine) motif of zinc enzymes: nickel, cobalt and zinc complexes and a comparison with metal binding in carbonic anhydrase. Eur. J. Inorg. Chem., 2003, 2003, 3945-3951.
126. Kunz, P. C.; Kassack, M. U.; Hamacher, A.; Spingler, B. Imidazole-based phosphane gold(I) complexes as potential agents for cancer treatment: Synthesis, structural studies and antitumour activity. Dalton Trans., 2009, 7741-7747.
127. Cinellu, M. A.; Minghetti, G.; Pinna, M. V.; Stoccoro, S.; Zucca, A.; Manassero, M.; Sansoni, M. Micro -Oxo and alkoxo complexes of gold(III) with 6-alkyl-2,2'-bipyridines. Synthesis, characterization and X-ray structures. J. Chem. Soc., Dalton Trans., 1998, 1735-1741.
128. Cinellu, M. A.; Minghetti, G.; Pinna, M. V.; Stoccoro, S.; Zucca, A.; Manassero, M. Gold(III) derivatives with anionic oxygen ligands: mononuclear hydroxo, alkoxo and acetato complexes. Crystal structure of [Au(bpy)(OMe)2] [PF6]. Dalton Trans., 2000, 1261-1265.
129. Casini, A.; Cinellu, M. A.; Minghetti, G.; Gabbiani, C.; Coronnello, M.; Mini, E.; Messori, L. Structural and solution chemistry, antiproliferative effects, and dna and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. J. Med. Chem., 2006, 49, 5524-5531.
130. Gabbiani, C.; Casini, A.; Messori, L.; Guerri, A.; Cinellu, M. A.; Minghetti, G.; Corsini, M.; Rosani, C.; Zanello, P.; Arca, M. Structural characterization, solution studies, and DFT calculations on a series of binuclear Gold(III) Oxo complexes: relationships to biological properties. Inorg. Chem., 2008, 47, 2368-2379.
131. Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu, M. A.; Minghetti, G.; Fregona, D.; Fiebig, H.-H.; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J. Biol. Inorg. Chem., 2009, 14, 1139-1149.
132. Magherini, F.; Modesti, A.; Bini, L.; Puglia, M.; Landini, I.; Nobili, S.; Mini, E.; Cinellu, M.; Gabbiani, C.; Messori, L. Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J. Biol. Inorg. Chem., 2010, 15, 573-582.
133. Ronconi, L.; Giovagnini, L.; Marzano, C.; Bettio, F.; Graziani, R.; Pilloni, G.; Fregona, D. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in Vitro antitumor activity. Inorg. Chem., 2005, 44, 1867-1881.
134. Marzano, C.; Trevisan, A.; Giovagnini, L.; Fregona, D. Synthesis of a new platinum(II) complex: anticancer activity and nephrotoxicity in vitro. Toxicol. in Vitro 2002, 16, 413-419.
135. Zhang, X.; Frezza, M.; Milacic, V.; Ronconi, L.; Fan, Y.; Bi, C.; Fregona, D.; Dou, Q. P. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. J. Cell. Biochem., 2010, 109, 162-172.
136. n+ compounds: synthesis and cytotoxic properties. Chem. Eur. J. 2006, 12, 5253-5266.
137. Yan, J. J.; Chow, A. L.-F.; Leung, C.-H.; Sun, R. W.-Y.; Ma, D.-L.; Che, C.-M. Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. Chem. Commun., 2010, 46, 3893-3895.
138. McKeage, M. J.; Maharaj, L.; Berners-Price, S. J. Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. Coord. Chem. Rev., 2002, 232, 127-135.
139. Berners-Price, S. J. Targeting the mitochondrial cell death pathway with gold complexes. Chem. Aust., 2004, 71, 10-12.
140. Berners-Price, S. J.; Filipovska, A. The design of gold-based, mitochondria-targeted chemotherapeutics. Aust. J. Chem., 2008, 61, 661-668.
141. Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Day, D. A. Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents. J. Inorg. Biochem., 2004, 98, 1642-1647.
142. Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Skelton, B. W.; White, A. H. Dinuclear gold(I) complexes of bridging bidentate carbene ligands: synthesis, structure and spectroscopic characterisation. Dalton Trans., 2004, 1038-1047.
143. Barnard, P. J.; Wedlock, L. E.; Baker, M. V.; Berners-Price, S. J.; Joyce, D. A.; Skelton, B. W.; Steer, J. H. Luminescence studies of the intracellular distribution of a dinuclear gold(I) N-heterocyclic carbene complex. Angew. Chem. Int. Ed. 2006, 45, 5966-5970.